Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11281762 | 0.86 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNAGAAPKM | |
| SCHEMBL11179145 | 0.85 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1LMNAGAAKDM4E | |
| SCHEMBL15746904 | 0.82 | POLB (0.54) | SMN1; SMN2ALDH1A1LMNAGAAKDM4E | |
| SCHEMBL11076103 | 0.81 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1LMNAGAAKDM4E | |
| SCHEMBL11632958 | 0.81 | MAPT (0.55) | SMN1; SMN2LMNAGAAKDM4EPKM | |
| SCHEMBL7373951 | 0.81 | LMNA (0.62) | SMN1; SMN2LMNAGAAKDM4EMAPT | |
| SCHEMBL3919280 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1LMNAGAATSHR | |
| SCHEMBL11177132 | 0.81 | LMNA (0.48) | SMN1; SMN2ALDH1A1LMNAGAAPKM | |
| SCHEMBL29543150 | 0.80 | KDM4E (0.62) | ALDH1A1LMNAGAAKDM4ETSHR | |
| SCHEMBL35247 | 0.80 | LMNA (0.66) | ALDH1A1LMNAGAAKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271918-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271918-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2022035804-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-2590948-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | Wyeth LLC (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004748-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-7232467-B2 | Dyeing hair with capped diazonium compound; intense, striking coloration; light, shampoo and rub fastness; storage stability; nondamaging, nonstaining | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-06-19 | — | — | US | disclosed |
| EP-0093488-A2 | Nortropyl benzopyrrolinone compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-11-09 | — | — | EP | disclosed |
| EP-0023964-B1 | PHENYLIMINOTHIAZOLINE DERIVATIVES, THEIR PREPARATION AND INTERMEDIATES THEREFOR, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR PRODUCTION | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-16 | — | — | EP | disclosed |
| US-4346088-A | ANTILIPEMICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-08-24 | — | — | US | disclosed |
| EP-0023964-A1 | Phenyliminothiazoline derivatives, their preparation and intermediates therefor, pharmaceutical preparations containing them and their production | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271918-A1 | SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP1 | SMN1; SMN2 2091/4885ALDH1A1 1387/4885LMNA 3727/4885 |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | NR1H2, NR1H3, NR1H4 | SMN1; SMN2 4218/4885ALDH1A1 770/4885LMNA 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.